-
Literature Sharing | "Uncertain" UroVysion Fluorescence In Situ Hybridization Results: Clinical Significance of Diagnostic Terms
Time of Update: 2021-04-28
The UroVysion FISH results of some cases in clinical testing have 1-3 abnormal cells.
The purpose of this study is to clarify the incidence and clinical significance of these uncertain UroVysion results.
Overall, the incidence of secondary malignancies in the UroVysion group with uncertain results (14/59, 23.
-
Fancy contenders for antibody drugs
Time of Update: 2021-04-28
▲The second TG-Bio immune technology conference in Bioogo 2021 ▲Currently, there are more than one hundred antibody drugs approved for marketing worldwide, involving 58 targets.
In addition, these small molecule inhibitors may not directly compete with antibody drugs with the same target.
-
Nature: Bacterial peptides on the surface of tumor cells are expected to become a new target for cancer immunotherapy
Time of Update: 2021-04-28
com" target="_blank">/---Cancer immunotherapy may be promoted in an unexpected direction: bacteria residing in tumor cells.
com/course/tags/%E7%BB%86%E8%83%9E%E7%94%9F%E7%89%A9%E5%AD%A6/">Cell Biology at the Weizmann Institute of Science has studied molecular "markers"-protein fragments on the cell surface, or peptides, which can mark cancer cells as foreign and may therefore become immunotherapy.
-
The latest version of the treatment guidelines for venous thromboembolism in cancer patients
Time of Update: 2021-04-28
Key Points For patients who have received systemic treatment and are judged to be at high (rather than low or moderate) risk of thrombosis, it is recommended that DOAC be used for primary prevention.
American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer.
-
Early tumor screening requires the right remedy
Time of Update: 2021-04-28
4. Liver Cancer Primary liver malignant tumors originate from the epithelial or mesenchymal tissues of the liver, have a high mortality rate, and develop rapidly, and most of them are difficult to control for a long time.
-
Diffuse large B-cell lymphoma requires clear factors and efficacy evaluation before treatment
Time of Update: 2021-04-28
In addition, the PET/CT assessment results of DLBCL patients after 2 to 4 cycles of treatment may affect the patient's prognosis.
Therefore, it is not recommended to guide the follow-up treatment of DLBCL based on the results of mid-term PET/CT evaluation outside of clinical trials.
-
Colonoscopy should be done at the age of 45! The Stanford team analyzed the big data of 6 million people and found that the first colonoscopy between the ages of 45-49 is associated with a 50% reduction in the risk of colorectal cancer | Clinical Discovery
Time of Update: 2021-04-28
To talk about medical examinations and tests that make ordinary people "fearful", then gastroscopy colonoscopy is definitely on the list. Singularity cakes are often privately chatted by anxious fri
-
Harvard's HPV vaccination should be given as early as possible, and the cancer prevention effect will be reduced for those over 26!
Time of Update: 2021-04-28
People over 26 years of age are vaccinated with HPV vaccine effectiveness and cancer prevention potential is low.
-
Don't pick wild mushrooms on the side of the road? But this kind of mushroom is "sweet", is it right to fight cancer and control sugar?
Time of Update: 2021-04-28
Another study published in the Journal of Functional Foods showed that eating white mushrooms can produce subtle changes in the microbial community in the intestines, thereby improving the regulation of glucose in the liver.
-
Blockbuster therapy allows early-stage lung cancer patients to "survive without cancer" longer, and it has been launched in China
Time of Update: 2021-04-28
▎Editor of WuXi AppTec's content team On March 22, Genentech, a subsidiary of Roche, announced that its PD-L1 antibody Tecentriq (atezolizumab, atezolizumab) is in the treatment of early stage non-small cell lung cancer NSCLC) patients reached the primary endpoint in a phase 3 clinical trial.
-
Friends who want to study the feedforward loop quickly look over
Time of Update: 2021-04-28
The effect of microgravity on bone loss and drug screening 1) The author analyzed the gene and miRNA expression in the skeletal system subnet (Figure 6D).
-
Huazhong University of Science and Technology and other organizations cooperated with Chen Gang/Zhang Qinghua and others to develop new classification methods to better treat cervical cancer
Time of Update: 2021-04-28
On March 18, 2021, Chen Gang, Zhang Qinghua and Hu Zheng of Huazhong University of Science and Technology jointly published an online publication titled "A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical" in Advanced Science (IF=16) Cancer" research paper, the study identified patient-specific somatic mutations that caused NACT non-response through whole exome sequencing.
-
PROTAC new technology opens a new field of tumor targeted therapy
Time of Update: 2021-04-28
▶ After the establishment of Arvinas, companies such as C4 Therapeutics and Kymera Therapeutics were established one after another, dedicated to exploring the therapeutic potential of small molecule protein degradation agents, and constantly making new contributions in the field of PROTAC technology.
▶ ARV-110, an oral protein degrading agent targeting AR, is the world's first PROTAC drug to enter clinical trials.
-
Do you really understand the platinum drugs commonly used in clinical practice?
Time of Update: 2021-04-28
Figure 1 The chemical structure of cisplatin ■ The second-generation platinum-based carboplatin was developed in the 1980s and went on the market in the United States in 1986.
-
See the trick: What should I do if PD-1/PD-L1 immunotherapy drugs are resistant?
Time of Update: 2021-04-27
· Internal reasons for drug resistance: tumor cells are very cunning and will bypass immunotherapy through many mechanisms, such as affecting neoantigen expression, antigen presentation, and affecting immune co-suppressive signals.
-
Sci Adv | Zhao Shulin/Zhang Liangliang's research team establishes new methods for photoacoustic imaging and photothermal treatment of tumor growth
Time of Update: 2021-04-27
On March 19, 2021, the Zhao Shulin/Zhang Liangliang research team of Guangxi Normal University University published an online research paper entitled A tumor microenvironment–induced absorption red-shifted polymer nanoparticle for simultaneously activated photoacoustic imaging and photothermal therapy in Science Advances.
-
Summit Dialogues to Participate in the Grand Event | Focus on the first cwCLL and iwCLL joint conference
Time of Update: 2021-04-27
On March 20, 2021, the 4th China Chronic Lymphocytic Leukemia Conference and the 1st China Chronic Lymphocytic Leukemia Working Group (cwCLL) and International Chronic Lymphocytic Leukemia Working Gr
-
"Li" creates extraordinary, "Da" has promising │ Daboshu® new indication is launched, rewriting the first-line treatment pattern of non-squamous NSCLC in China
Time of Update: 2021-04-27
Foreword Lung cancer is currently the number one malignant tumor in China in terms of morbidity and mortality1. Among all types of lung cancer, 80%-85%2 belong to non-small cell lung cancer (NSCLC),
-
Ascent Pharmaceuticals Nectinib is included in the proposed breakthrough treatment, and it is China's first BCR-ABL targeted CML drug
Time of Update: 2021-04-27
Screenshot source: CDE official website HQP1351 is an original Class 1 new drug under research by Ascent Pharmaceuticals, a new third-generation BCR-ABL tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI), used to treat first- and second-generation TKI resistance Chronic Myelogenous Leukemia (CML), especially for CML patients with T315I mutation, has a good effect.
-
Shanghai Jiaotong University Duan Yourong/Lin Houwen/Liao Hongze The development of new protein inhibitors has important reference significance for the control of tumor blood-borne metastasis
Time of Update: 2021-04-27
This study generally demonstrates the feasibility of using DR6/APP interaction to regulate transendothelial migration of blood-borne tumor cells, and provides PEG-tAHP-DRI as a DR6/APP interaction for the development of anti-blood-borne metastasis therapies A novel and promising inhibitor.
